Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18356110 | 1.00 | CA2 (0.32) | CA2 | |
| SCHEMBL20267712 | 1.00 | CA2 (0.32) | CA2 | |
| SCHEMBL13381150 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL14044273 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL21574813 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL10314717 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL17616015 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL12230294 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL10314711 | 0.78 | CA2 (0.32) | CA2 | |
| SCHEMBL11027021 | 0.77 | CA2 (0.31) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4514807-B1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4514806-B1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4514808-B1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340570-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340571-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250340572-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| EP-4522622-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4514806-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4514808-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-4514807-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023220439-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023212239-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212237-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023212231-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340572-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SF3A2, SF3A3 | CA2 4848/4885 |
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | CA2 4095/4885 |
| US-20250340570-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SF3A2, SMN1; SMN2 | CA2 4848/4885 |
| US-20250340571-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, RBM22, U2AF1 | CA2 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.